Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company, has announced an updated time for its presentation at the 2024 Cantor Global Healthcare Conference. The company's Chair and CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation on Thursday, September 19, 2024, at 8:00 a.m. Eastern time.
Keros focuses on developing novel therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. The presentation will be available via live audio webcast, with an archived replay accessible on the company's investor relations website for up to 90 days after the event.
Keros Therapeutics (Nasdaq: KROS), una compagnia biofarmaceutica in fase clinica, ha annunciato un aggiornamento sull'orario della sua presentazione alla 2024 Cantor Global Healthcare Conference. Il Presidente e CEO dell'azienda, Jasbir S. Seehra, Ph.D., parteciperà a una presentazione in formato 'fireside chat' giovedì, 19 settembre 2024, alle 8:00 ora orientale.
Keros si concentra sullo sviluppo di terapiche innovative per disturbi legati alla segnalazione disfunzionale della famiglia di proteine del fattore di crescita trasformante-beta (TGF-ß). La presentazione sarà disponibile tramite webcast audio in diretta, con una replica archiviata accessibile sul sito delle relazioni con gli investitori dell'azienda per un massimo di 90 giorni dopo l'evento.
Keros Therapeutics (Nasdaq: KROS), una empresa biofarmacéutica en etapa clínica, ha anunciado una actualización sobre el horario de su presentación en la 2024 Cantor Global Healthcare Conference. El Presidente y CEO de la compañía, Jasbir S. Seehra, Ph.D., participará en una presentación en formato de charla informal el jueves, 19 de septiembre de 2024, a las 8:00 a.m. hora del Este.
Keros se centra en el desarrollo de terapias innovadoras para trastornos relacionados con la señalización disfuncional de la familia de proteínas del factor de crecimiento transformante-beta (TGF-ß). La presentación estará disponible a través de un webcast de audio en vivo, con una repetición archivada accesible en el sitio web de relaciones con inversores de la compañía por hasta 90 días después del evento.
케로스 테라퓨틱스 (Nasdaq: KROS), 임상 단계의 생명공학 회사,는 2024 칸토 글로벌 헬스케어 컨퍼런스를 위한 발표 시간을 업데이트 했습니다. 회사의 회장 겸 CEO인 자스비르 S. 시라, 박사가 2024년 9월 19일 목요일 오전 8시(동부 표준시)에 열린 파이어사이드 채팅에 참여할 예정입니다.
케로스는 형질전환 성장 인자-베타(TGF-ß) 단백질 계열과 관련된 기능 이상 신호 장애에 대한 혁신적인 치료제를 개발하는 데 주력하고 있습니다. 발표는 실시간 오디오 웹캐스트를 통해 제공되며, 이벤트 후 최대 90일간 회사의 투자자 관계 웹사이트에서 아카이브된 재생을 이용할 수 있습니다.
Keros Therapeutics (Nasdaq: KROS), une entreprise biopharmaceutique en phase clinique, a annoncé une mise à jour concernant l'heure de sa présentation lors de la 2024 Cantor Global Healthcare Conference. Le Président et CEO de l'entreprise, Jasbir S. Seehra, Ph.D., participera à une présentation sous forme de discussion informelle le jeudi 19 septembre 2024 à 8h00, heure de l'Est.
Keros se concentre sur le développement de nouvelles thérapies pour les troubles liés à une signalisation dysfonctionnelle de la famille des protéines du facteur de croissance transformant-bêta (TGF-ß). La présentation sera disponible via un webcast audio en direct, avec une rediffusion archivée accessible sur le site des relations investisseurs de l'entreprise pendant 90 jours après l'événement.
Keros Therapeutics (Nasdaq: KROS), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat eine Aktualisierung zu seiner Präsentation auf der 2024 Cantor Global Healthcare Conference bekannt gegeben. Der Vorsitzende und CEO des Unternehmens, Jasbir S. Seehra, Ph.D., wird am Donnerstag, den 19. September 2024, um 8:00 Uhr Eastern Time an einem Fireside Chat teilnehmen.
Keros konzentriert sich auf die Entwicklung neuartiger Therapeutika für Störungen, die mit dysfunktionalen Signalübertragungen der Familie der Transforming Growth Factor-Beta (TGF-ß) Proteine verbunden sind. Die Präsentation wird über ein Live-Audio-Webcast verfügbar sein, und eine archivierte Wiederholung wird bis zu 90 Tage nach der Veranstaltung auf der Investor-Relations-Website des Unternehmens zugänglich sein.
- None.
- None.
LEXINGTON, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the 2024 Cantor Global Healthcare Conference that will now begin at 8:00 a.m. Eastern time on Thursday, September 19, 2024.
A live audio webcast of the fireside chat presentation will be available at https://wsw.com/webcast/cantor22/kros/2112021 and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of the event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. The Company is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ second product candidate, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension for the treatment of cardiovascular disorders. Keros’ third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
FAQ
When is Keros Therapeutics (KROS) presenting at the 2024 Cantor Global Healthcare Conference?
Who will be representing Keros Therapeutics (KROS) at the 2024 Cantor Global Healthcare Conference?
How can investors access Keros Therapeutics' (KROS) presentation at the 2024 Cantor Global Healthcare Conference?
What is the main focus of Keros Therapeutics' (KROS) research and development?
